Generic Name: ustekinumab
Brand Name: Stelara
Manufacturer: Janssen Inc.
Indications: Ulcerative colitis
Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with moderately to severely active ulcerative colitis who have failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a biologic, or have failed or were intolerant to treatment with a biologic.
Submission Type: New Indication
Project Status: Received
Companion Diagnostics: No
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||July 12, 2019|
|Patient group input closed||September 03, 2019|
|Patient input summary sent for review to patient input groups||-|
|Patient group comments on input summary closed||-|
|Submission received||August 12, 2019|
|Submission accepted for review||August 26, 2019|
|Draft CADTH review report(s) sent to applicant||-|
|Comments from applicant on draft CADTH review report(s) received||-|
|CADTH review team's comments on draft CADTH review report(s) sent to applicant||-|
|Canadian Drug Expert Committee (CDEC) meeting||-|
|CDEC recommendation sent to applicant and drug plans||-|